TNF Pharmaceuticals (LTS:0A8D) Insider Ownership : 32.65 % (As of Apr. 13, 2025)

View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TNF Pharmaceuticals's insider ownership is 32.65%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TNF Pharmaceuticals's Institutional Ownership is 0.87%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TNF Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 89.26%.

TNF Pharmaceuticals Insider Ownership Historical Data

The historical data trend for TNF Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Insider Ownership Chart

TNF Pharmaceuticals Historical Data

The historical data trend for TNF Pharmaceuticals can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Insider Ownership	2.03	2.03	32.65	32.65	32.65	32.65	32.65	32.65	32.65	32.65

TNF Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

TNF Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

TNFA:USA

Address

855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://tnfpharma.com

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

TNF Pharmaceuticals Headlines

No Headlines